Dr Paul W Alberti, MD | |
31 Broadway, North Haven, CT 06473-2304 | |
(203) 234-1324 | |
(203) 239-3047 |
Full Name | Dr Paul W Alberti |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 31 Broadway, North Haven, Connecticut |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821101080 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | 027413 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Paul W Alberti, MD 31 Broadway, North Haven, CT 06473-2304 Ph: (203) 234-1324 | Dr Paul W Alberti, MD 31 Broadway, North Haven, CT 06473-2304 Ph: (203) 234-1324 |
News Archive
To help draw attention to National Child Health Day (today), the Preventive Cardiovascular Nurses Association (PCNA) has released findings from a new national consumer survey and launched a campaign to educate families about heart disease, the leading cause of death in the U.S.
Varian Medical Systems, Inc. today announced that CURE Foundation has placed an order for five Varian TrueBeamâ„¢ systems for stereotactic radiosurgery and radiation therapy.
Major rainfall across most of Texas triggering hordes of mosquitos coupled with seemingly constant mosquito-related Zika virus media reports from around the globe may have set the stage perfectly for what one researcher deems as a very significant discovery in man's war against earth's leading human disease carrier.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.
Akonni Biosystems, a developer of low-cost, multiplex molecular diagnostic testing systems, today announced that the United States Patent and Trademark Office issued a patent on July 20, 2010 for its method for rapidly purifying nucleic acids. U.S. Patent No. 7,759,112 entitled, "Apparatus, system, and method for purifying nucleic acids" protects the Company's use of its pioneering nucleic acid binding matrix when inserted into a pipette tip, tubing or cartridge for nucleic acid purification. The patent is owned by Akonni Biosystems.
› Verified 1 days ago
Dr. Thomas G Takoudes, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 31 Broadway, North Haven, CT 06473 Phone: 203-234-1324 Fax: 203-239-3047 | |
Tapan Dilipkumar Patel, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 31 Broadway Fl 2, North Haven, CT 06473 Phone: 203-234-1324 Fax: 203-239-3047 | |
Dr. Agnes Czibulka, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 31 Broadway, North Haven, CT 06473 Phone: 203-234-1324 Fax: 203-239-3047 |